<DOC>
	<DOCNO>NCT00274235</DOCNO>
	<brief_summary>Malaria pregnancy one important preventable cause low birthweight worlwide major cause severe maternal anaemia contribute maternal mortality . Intermittent Preventive Treatment ( IPT ) sulfadoxine-pyrimethamine ( SP ) currently adopt government recommendation malaria control pregnancy Benin , emergence spread resistance SP justify evaluation alternative anti-malarial drug . Mefloquine ( MQ ) , proven effective reasonably safe indication , may interest alternative SP . The aim trial compare efficacy safety sulfadoxine-pyrimethamine mefloquine IPT . It equivalent study design test hypothesis MQ efficacious SP prevent malaria pregnancy , could replace SP resistance Plasmodium falciparum becomes elevate . Primary endpoint proportion infant low birthweight . Secondary endpoint proportion mother placental plasmodial infection , proportion mother anaemia delivery .</brief_summary>
	<brief_title>Intermittent Preventive Treatment During Pregnancy Benin</brief_title>
	<detailed_description>The trial conduct two maternity clinic Ouidah , 40km Cotonou . A total 1600 woman select randomised receive either SP ( 1500 mg sulfadoxine 75 mg pyrimethamine ) MQ ( 15 mg/kg ) twice pregnancy ante-natal clinic ( ANC ) visit . The first dose give 16 28 week gestation , second 30 36 week , least one month first dose . Women visit home within one week initial subsequent ANC visit check adverse reaction due study drug . Peripheral blood sample collect ANC visit ass haemoglobin level parasitemia . Peripheral , placental , cord blood sample collect delivery haematological determination parasitological examination . Birthweight record gestational age assess Ballard method . The mother child assess general health status six week birth .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>Pregnancy 16 28 week gestation Residence near maternity clinic Intention continue antenatal care deliver study maternity clinic Ability take drug oral route Written inform consent ( parent guardian age &lt; 18 year ) Pregnancy prior 16 week 28 week gestation Previous suspect reaction sulfadoxinepyrimethamine mefloquine History neurological psychiatric event Intake sulfadoxinepyrimethamine mefloquine within 4 week enrollment Current treatment halofantrine</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Prevention</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Low birthweight</keyword>
	<keyword>Anemia</keyword>
	<keyword>Africa</keyword>
</DOC>